Purple Biotech Ltd.
Develops cancer therapies to overcome tumor immune evasion and drug resistance.
PPBT | TA
Overview
Corporate Details
- ISIN(s):
- IL0007650166
- LEI:
- Country:
- Israel
- Address:
- Oppenheimer 4, 7670104 Rehovot
- Website:
- https://purple-biotech.com/
- Sector:
- Manufacturing
Description
Purple Biotech Ltd. is a clinical-stage company that develops first-in-class therapies for cancer patients. The company focuses on advancing treatments designed to overcome tumor immune evasion and drug resistance, with the goal of providing effective and durable therapeutic solutions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-06 16:10 |
Purple Biotech Reports Second Quarter 2025 Financial Results
|
English | 275.0 KB | ||
| 2025-08-06 16:10 |
Purple Biotech Reports Second Quarter 2025 Financial Results
|
English | 36.9 KB | ||
| 2025-07-23 16:11 |
6K: Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Prog…
|
English | 196.4 KB | ||
| 2025-07-23 16:11 |
6K: Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Prog…
|
English | 36.8 KB | ||
| 2025-06-23 16:18 |
6K: Purple Biotech Announces Highlights Significant Advantages of the Novel CAP…
|
English | 191.8 KB | ||
| 2025-06-23 16:18 |
6K: Purple Biotech Announces Highlights Significant Advantages of the Novel CAP…
|
English | 36.9 KB | ||
| 2025-06-17 17:08 |
6K: Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients w…
|
English | 214.2 KB | ||
| 2025-06-17 17:08 |
6K: Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients w…
|
English | 36.8 KB | ||
| 2025-06-04 16:12 |
Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Pla…
|
English | 156.4 KB | ||
| 2025-06-04 16:12 |
Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Pla…
|
English | 36.6 KB | ||
| 2025-05-21 16:22 |
Purple Biotech Reports First Quarter 2025 Financial Results
|
English | 219.5 KB | ||
| 2025-05-21 16:22 |
Purple Biotech Reports First Quarter 2025 Financial Results
|
English | 36.8 KB | ||
| 2025-05-12 16:39 |
6K: Purple Biotech Appoints Shai Lankry as Chief Financial Officer
|
English | 175.6 KB | ||
| 2025-05-12 16:39 |
6K: Purple Biotech Appoints Shai Lankry as Chief Financial Officer
|
English | 36.6 KB | ||
| 2025-05-07 01:45 |
6K: Purple Biotech Corporate Presentation May 2025
|
English | 30.7 MB |
Automate Your Workflow. Get a real-time feed of all Purple Biotech Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Purple Biotech Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Purple Biotech Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
